Bicycle Therapeutics (BCYC) Form 144: $4,563 Proposed Sale

Rhea-AI Filing Summary

Bicycle Therapeutics plc (BCYC) filed a Form 144 notifying a proposed sale of 543 shares of Common Stock through Stifel Nicolaus & Company Inc with an aggregate market value of $4,563. The filing lists the securities as to be sold on or about 10/02/2025 on Nasdaq. The shares were acquired as Restricted Stock Units from the issuer on 10/02/2025 (1,000 units) and 10/03/2025 (593 units). Prior reported sales by the same person in the past three months total 304 shares for gross proceeds of $2,191.

Positive

• Planned sale disclosed via Form 144 showing regulatory compliance
• Broker-dealer execution identified as Stifel Nicolaus & Company Inc

Negative

• Recent insider sales of 304 shares in July 2025 totaling $2,191
• Shares derived from RSUs issued on 10/02/2025 and 10/03/2025 are being sold soon after acquisition

Insights

Securities Compliance Analyst

Form 144 notifies a small, rule-compliant insider sale via broker on Nasdaq.

The filing shows a proposed sale of 543 shares with an aggregate market value of $4,563 through Stifel Nicolaus, indicating the filer intends to use a broker-dealer to execute the transaction.

The securities were issued as Restricted Stock Units on 10/02/2025 and 10/03/2025, and the filer disclosed prior open-market sales of 304 shares in July 2025 totaling $2,191, which are reported for aggregation under Rule 144.

FAQ

What does Bicycle Therapeutics (BCYC) report on this Form 144?

The filer notifies a proposed sale of 543 shares of common stock with an aggregate market value of $4,563 to be executed through Stifel Nicolaus on or about 10/02/2025 on Nasdaq.

How were the shares being sold acquired?

The shares were acquired as Restricted Stock Units from the issuer on 10/02/2025 (1,000 units) and 10/03/2025 (593 units) and paid as Equity Compensation.

Did the filer sell any shares recently?

Yes, the filer sold 204 shares on 07/02/2025 for $1,447 and 100 shares on 07/03/2025 for $744, totaling 304 shares and $2,191 in gross proceeds.

Which broker will handle the sale?

The designated broker is Stifel Nicolaus & Company Inc, located at 501 N Broadway St. Louis, MO 63102.

On which exchange will the sale occur?

The proposed sale is identified for execution on Nasdaq.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/02/2025 - 05:21 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001983944
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BICYCLE THERAPEUTICS PLC
SEC File Number	001-38916
Address of Issuer	BLOCKS A & B, PORTWAY BUILDING GRANTA PARK, GREAT ABINGTON CAMBRIDGE UNITED KINGDOM CB21 6GS
Phone	011441223261503
Name of Person for Whose Account the Securities are To Be Sold	Thompson Travis Alvin
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	543	4563.00	49868567	10/02/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	10/02/2025	Restricted Stock Units	Issuer			1000	10/02/2025	Equity Compensation
Common Stock	10/03/2025	Restricted Stock Units	Issuer			593	10/03/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Travis Thompson Blocks A & B Portway Building Cambridge X0 CB21 6GS	Common Stock	07/02/2025	204	1447.00
Travis Thompson Blocks A & B Portway Building Cambridge X0 CB21 6GS	Common Stock	07/03/2025	100	744.00

144: Remarks and Signature

Remarks
Date of Notice	10/02/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ James Weimer, as a duly authorized representative of STIFEL, as attorney-in-fact for Travis Thompson
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)